ABILIFY 7.5 mg/ml solution for injection
*Company:
Otsuka Pharmaceutical UK Ltd.Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
What is a Patient Information Leaflet and why is it useful?
A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine packaging. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Changes to the PIL after your medicine was packed may mean that the version on medicines.ie may differ from the version found with your medicine. You can compare the “Leaflet prepared or revised date” towards the end of the leaflet in the pack with the version that is on the website to find out if there have been any changes to the information since your medicine was packed.
What is an XPIL?
Some pharmaceutical companies have chosen to display PIL in a HTML text only “Print View” version, called an XPIL, as well as in PDF format. The XPIL is designed for people who are blind or partially-sighted.
Abilify 7
Last updated: 14/04/22
Otsuka Pharmaceutical UK Ltd.
Address:
Otsuka Pharmaceuticals (U.K.) Ltd., 2 Windsor Dials, Arthur Road, Windsor SL4 1RS, United KingdomMedical Information E-mail:
medical.information@otsuka-europe.comTelephone:
44 (0)203 747 5300Stock Availability:
n/a